Angiotensin-converting enzyme 2 as a therapeutic target for heart failure

Current Heart Failure Reports

Volumn 11, Issue 1, 2014, Pages 58-63

  Chamsi Pasha, Mohammed A R ^a   Shao, Zhili ^b   Tang, W H Wilson ^b,c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c NONE   (United States)

Author keywords

Angiotensin (1 7); Angiotensin converting enzyme 2; Heart failure; Renin angiotensin system

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; ANGIOTENSIN[1-7];

ARTICLE; DIASTOLIC DYSFUNCTION; HEART FAILURE; HEART PROTECTION; HORMONE SYNTHESIS; HUMAN; HYPERTENSION; NONHUMAN; SYSTOLIC DYSFUNCTION;

ANGIOTENSIN I; CARDIOVASCULAR AGENTS; HEART FAILURE; HUMANS; HYPERTENSION; MOLECULAR TARGETED THERAPY; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A; RENIN-ANGIOTENSIN SYSTEM; VENTRICULAR REMODELING;

EID: 84896730319     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-013-0178-0     Document Type: Article

References (46)

1. Wang W, Bodiga S, Das SK, Lo J, Patel V, Oudit GY. Role of ACE2 in diastolic and systolic heart failure. Heart Fail Rev. 2012;17(4-5):683-91.
2. • Oudit GY, Crackower MA, Backx PH, Penninger JM. The role of ACE2 in cardiovascular physiology. Trends Cardiovasc Med. 2003;13(3):93-101. Comprehensive review on the current physiologic understanding of ACE2 in cardiovascular diseases. (Pubitemid 36411803)
3. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem. 2000;275(43):33238-43.
4. Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2000;87(5):E1-9.
5. Burrell LM, Harrap SB, Velkoska E, Patel SK. The ACE2 gene: its potential as a functional candidate for cardiovascular disease. Clin Sci (Lond). 2013;124(2):65-76.
6. Iwata M, Cowling RT, Yeo SJ, Greenberg B. Targeting the ACE2-Ang-(1-7) pathway in cardiac fibroblasts to treat cardiac remodeling and heart failure. J Mol Cell Cardiol. 2011;51(4):542-7.
7. •• Oudit GY, Penninger JM. Recombinant human angiotensin-converting enzyme 2 as a new renin-angiotensin system peptidase for heart failure therapy. Curr Heart Fail Rep. 2011;8(3):176-83. First demonstration of the feasibility and beneficial effects of recumbinant human ACE2 as potential therapy.
8. Vickers C, Hales P, Kaushik V, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem. 2002;277(17):14838-43. (Pubitemid 34952556)
9. Fraga-Silva RA, Costa-Fraga FP, Murca TM, et al. Angiotensin-converting enzyme 2 activation improves endothelial function. Hypertension. 2013;61(6):1233-8.
10. Keidar S, Gamliel-Lazarovich A, Kaplan M, et al. Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients. Circ Res. 2005;97(9):946-53. (Pubitemid 41552681)
11. Silva AC S e, Silveira KD, Ferreira AJ, Teixeira MM. ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis. Br J Pharmacol. 2013;169(3):477-92.
12. Zhong JC, Ye JY, Jin HY, et al. Telmisartan attenuates aortic hypertrophy in hypertensive rats by the modulation of ACE2 and profilin-1 expression. Regul Pept. 2011;166(1-3):90-7.
13. Clarke NE, Fisher MJ, Porter KE, Lambert DW, Turner AJ. Angiotensin converting enzyme (ACE) and ACE2 bind integrins and ACE2 regulates integrin signalling. PLoS One. 2012;7(4):e34747.
14. Lin Q, Keller RS, Weaver B, Zisman LS. Interaction of ACE2 and integrin beta1 in failing human heart. Biochim Biophys Acta. 2004;1689(3):175-8. (Pubitemid 38981593)
15. Sato T, Suzuki T, Watanabe H, et al. Apelin is a positive regulator of ACE2 in failing hearts. J Clin Invest 2013.
16. Zhong J, Basu R, Guo D, et al. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation. 2010;122(7):717-28. 718 p following 728.
17. • Kassiri Z, Zhong J, Guo D, et al. Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction. Circ Heart Fail. 2009;2(5):446-55. Important demonstration of the cardioprotective role of ACE2.
18. Tikellis C, Bernardi S, Burns WC. Angiotensin-converting enzyme 2 is a key modulator of the renin-angiotensin system in cardiovascular and renal disease. Curr Opin Nephrol Hypertens. 2011;20(1):62-8.
19. Oudit GY, Kassiri Z, Patel MP, et al. Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice. Cardiovasc Res. 2007;75(1):29-39. (Pubitemid 46873522)
20. Bodiga S, Zhong JC, Wang W, et al. Enhanced susceptibility to biomechanical stress in ACE2 null mice is prevented by loss of the p47(phox) NADPH oxidase subunit. Cardiovasc Res. 2011;91(1):151-61.
21. Huentelman MJ, Grobe JL, Vazquez J, et al. Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp Physiol. 2005;90(5):783-90. (Pubitemid 41406067)
22. Yamamoto K, Ohishi M, Katsuya T, et al. Deletion of angiotensin- converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II. Hypertension. 2006;47(4):718-26. (Pubitemid 43740244)
23. Santos RA, Ferreira AJ, ESAC Simoes. Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis. Exp Physiol. 2008;93(5):519-27. (Pubitemid 351595060)
24. Keidar S, Kaplan M, Gamliel-Lazarovich A. ACE2 Of the heart: from angiotensin I to angiotensin (1-7). Cardiovasc Res. 2007;73(3):463-9. (Pubitemid 46091776)
25. Grobe JL, Der Sarkissian S, Stewart JM, Meszaros JG, Raizada MK, Katovich MJ. ACE2 overexpression inhibits hypoxia-induced collagen production by cardiac fibroblasts. Clin Sci (Lond). 2007;113(8):357-64. (Pubitemid 47572276)
26. Zhao YX, Yin HQ, Yu QT, et al. ACE2 overexpression ameliorates left ventricular remodeling and dysfunction in a rat model of myocardial infarction. Hum Gene Ther. 2010;21(11):1545-54.
27. Lazartigues E, Feng Y, Lavoie JL. The two fACEs of the tissue renin-angiotensin systems: implication in cardiovascular diseases. Curr Pharm Des. 2007;13(12):1231-45. (Pubitemid 46739331)
28. Imai Y, Kuba K, Ohto-Nakanishi T, Penninger JM. Angiotensin-converting enzyme 2 (ACE2) in disease pathogenesis. Circ J. 2010;74(3):405-10.
29. Zisman LS, Keller RS, Weaver B, et al. Increased angiotensin-(1-7)- forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme Homologue ACE2. Circulation. 2003;108(14):1707-12. (Pubitemid 37243658)
30. Goulter AB, Goddard MJ, Allen JC, Clark KL. ACE2 gene expression is up-regulated in the human failing heart. BMC Med. 2004;2:19. (Pubitemid 39111859)
31. Ohtsuki M, Morimoto S, Izawa H, et al. Angiotensin converting enzyme 2 gene expression increased compensatory for left ventricular remodeling in patients with end-stage heart failure. Int J Cardiol. 2010;145(2):333-4.
32. • Epelman S, Tang WH, Chen SY, Van Lente F, Francis GS, Sen S. Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin- aldosterone system. J Am Coll Cardiol. 2008;52(9):750-4. Demonstration of the clinical relevance of ACE2 in humans by detecting circulating ACE2 activity and its associations with disease severity.
33. Epelman S, Shrestha K, Troughton RW, et al. Soluble angiotensin- converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes. J Card Fail. 2009;15(7):565-71.
34. Wang Y, Moreira Mda C, Heringer-Walther S, et al. Plasma ACE2 activity is an independent prognostic marker in Chagas' disease and equally potent as BNP. J Card Fail. 2010;16(2):157-63.
35. Shao Z, Shrestha K, Borowski AG, et al. Increasing serum soluble angiotensin-converting enzyme 2 activity after intensive medical therapy is associated with better prognosis in acute decompensated heart failure. J Card Fail. 2013;19(9):605-10.
36. Wysocki J, Ye M, Rodriguez E, et al. Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension. Hypertension. 2010;55(1):90-8.
37. Gallagher PE, Ferrario CM, Tallant EA. Regulation of ACE2 in cardiac myocytes and fibroblasts. Am J Physiol Heart Circ Physiol. 2008;295(6):H2373-9.
38. Lu N, Yang Y, Wang Y, et al. ACE2 gene polymorphism and essential hypertension: an updated meta-analysis involving 11,051 subjects. Mol Biol Rep. 2012;39(6):6581-9.
39. Vangjeli C, Dicker P, Tregouet DA, Shields DC, Evans A, Stanton AV. A polymorphism in ACE2 is associated with a lower risk for fatal cardiovascular events in females: the MORGAM project. J Renin Angiotensin Aldosterone Syst. 2011;12(4):504-9.
40. Zhou JB, Yang JK. Meta-analysis of association of ACE2 G8790A polymorphism with Chinese Han essential hypertension. J Renin Angiotensin Aldosterone Syst. 2009;10(1):31-4.
41. Der Sarkissian S, Huentelman MJ, Stewart J, Katovich MJ, Raizada MK. ACE2: A novel therapeutic target for cardiovascular diseases. Prog Biophys Mol Biol. 2006;91(1-2):163-98. (Pubitemid 43288989)
42. • Hernandez Prada JA, Ferreira AJ, Katovich MJ, et al. Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension. 2008;51(5):1312-7. Promising work on identifying ACE2 activators as therapeutic agents. (Pubitemid 351555943)
43. Ferreira AJ, Jacoby BA, Araujo CA, et al. The nonpeptide angiotensin-(1-7) receptor Mas agonist AVE-0991 attenuates heart failure induced by myocardial infarction. Am J Physiol Heart Circ Physiol. 2007;292(2):H1113-9.
44. Patel VB, Bodiga S, Fan D, et al. Cardioprotective effects mediated by angiotensin II type 1 receptor blockade and enhancing angiotensin 1-7 in experimental heart failure in angiotensin-converting enzyme 2-null mice. Hypertension. 2012;59(6):1195-203.
45. Masson R, Nicklin SA, Craig MA, et al: Onset of experimental severe cardiacfibrosis is mediated by overexpression of Angiotensin-converting enzyme 2.Hypertension 2009, 53(4):694-700.
46. Takahashi Y, Haga S, Ishizaka Y, Mimori A. Autoantibodies to angiotensin-converting enzyme 2 in patients with connective tissue diseases. Arthritis Res Ther. 2010;12(3):R85.